Will Someone Please Tell Me How a 1000$ Drug and Alcohol Treatment Program Is Going to “help” ?
Question by gotjanked: Will someone please tell me how a 1000$ drug and alcohol treatment program is going to “help” ?
fact is i will only quit if i want to. so its safe to say that “treatment” is nothing but a money making scam!!
Accident putting this in cancer section
r u kidding me i am not powerless and as soon as i believe that i am powerless iam beat! all a “addict” (person) needs is a lil backbone and some will power then he no longer a “addict” . and it dont cost a 1000$ for that !! come on man i need better answers
thank u roger!
Best answer:
Answer by sweet sue
No, its not a money making scheme. 1,000 is really cheap for a treatment center. But if you don’t want to quit it has no chance of working, It’s up to you to do the work to make it work. You can lead a horse to water but you can’t make him drink.
Know better? Leave your own answer in the comments!
Targacept to test drug as treatment for overactive bladder
Filed under: drug treatment
Targacept Inc. is taking its most well-known drug compound, TC-5214, in a new research direction in hope of bolstering research and eventually revenue. The Winston-Salem biotechnology company said Wednesday it is developing TC-5214 as a treatment …
Read more on Winston-Salem Journal
How A 0000 Drug Is Turning Alexion Into Biotech's New Innovation …
Filed under: drug treatment
His salvation: Soliris, launched in 2007 to treat a rare cause of anemia. In 2012 that drug will do more than $ 1.1 billion in revenue, with Wall Street expecting that figure to double again over the next three years. Its current net margin: 22 …
Read more on Forbes
Pfizer Wins Approval for Drug to Treat Type of Leukemia
Filed under: drug treatment
Pfizer Inc. (PFE), the world's largest drugmaker, won U.S. regulatory approval of its treatment for one of the four most common types of leukemia. The Food and Drug Administration cleared the drug, to be known as Bosulif, for adults with previously …
Read more on Bloomberg